Chr. Hansen Holding A/S Interim Report Q4 2022/23 - Seite 2

In connection with the merger agreement, Novozymes and Chr. Hansen have agreed on certain specific provisions in respect of distributions to their shareholders until completion of the proposed merger. Consistent with the merger agreement with Novozymes, the Board of Directors has decided to declare an interim dividend of DKK 7.72 or EUR 1.04 per share. The total dividend of EUR 137 million is equivalent to 55% of the adjusted profit for the period September 1, 2022 to August 31, 2023, and will be paid on October 17, 2023 (ex-dividend date of October 13, 2023).

Follow-up on 12-month outlook, September 1, 2022 – August 31, 2023

• Organic revenue growth of 11% (outlook July 6, 2023 9-11%)
• EBIT margin b.s.i. of 26.9% (outlook July 6, 2023 26-27%)
• Free cash flow b.a.s.i. of EURm 202 (outlook July 6, 2023 EURm 200-230)

Outlook, January 1, 2023 – December 31, 2023

In light of the performance for the first eight months of 2023, the outlook is adjusted for organic revenue growth and free cash flow b.a.s.i., while maintained for EBIT margin b.s.i. Organic growth for the remaining four months of 2023 is expected to be driven primarily by price growth including a positive impact from EUR-based pricing.

• Organic revenue growth is expected in the range of 10-12% (previously 9-12%)                                              
• EBIT margin b.s.i. is expected to be 26-27% (unchanged)
• Free cash flow b.a.s.i. is expected to be around EURm 190-230 (previously EURm 200-250)

The outlook for the calendar year 2023 is based on actual exchange rates until October 11, 2023, and for the remainder of the calendar year 2023 assuming constant exchange rates at the current level of EUR/USD rate of 1.06, compared to 1.09 at the time of the most recent outlook, provided on July 6, 2023. For further details on the outlook for the January 1, 2023 – December 31, 2023, please refer to page 9.

See attachment for full Q4 2022/23 interim report.

Contact details

Anders Mohr Christensen, VP Group Strategy & Investor Relations, [phone]
Disa Tuominen, Investor Relations Manager, [phone]

About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends, we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Attachment

• Chr. Hansen Interim Report Q4 2022_23